Nivolumab-induced eosinophilic fasciitis: a case report
- PMID: 32064454
- PMCID: PMC7010959
- DOI: 10.1093/rap/rkaa001
Nivolumab-induced eosinophilic fasciitis: a case report
Figures
References
-
- Kostine M, Rouxel L, Barnetche T. et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. Ann Rheum Dis 2018;77:393–8. - PubMed
-
- Khoja L, Maurice C, Chappell M. et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016;4:175–8. - PubMed
-
- Toussaint F, Hammon M, Erdmann M. et al. Checkpoint inhibitor-induced eosinophilic fasciitis following high eosinophilia associated with complete response. Rheumatology 2019;58:1875–7. - PubMed
-
- Lebeaux D, Francès C, Barete S. et al. Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients. Rheumatology 2012;51:557–61. - PubMed
LinkOut - more resources
Full Text Sources